Despite the use of aggressive chemotherapy, stage 4 high risk neuroblastoma still has very poor prognosis which is estimated at 25%. Metabolic radiotherapy with I 131 MIBG appears a feasible option to enhance the effects of chemotherapy. Seventeen patients having MIBGpositive residual disease received 4.1-11.1 mCi/kg of I 131 MIBG 7-10 days before initiating the high-dose chemotherapy cycle consisting of busulphan 16 mg/kg and melphalan 140 mg/m 2 followed by PBSC infusion. We compared the toxicity in these patients to that seen in 15 control subjects with neuroblastoma who underwent a PBSC transplant without MIBG therapy. We observed greater toxic involvement of the gastrointestinal system in children treated with I strategy includes inductive chemotherapy, mainly based on ozaphorines and platine derivatives followed by surgery and a consolidation phase including megatherapy with stem cell rescue. Conditioning regimens combining high-dose chemotherapy with total body irradiation have been abandoned due to unsatisfactory results and severe late effects. In a Children's Cancer Group (CCG) study, the event-free survival (EFS) of children receiving high-dose (HD) chemotherapy with peripheral blood stem cell transplantation (PBSC) rescue was 34% reaching 46% when followed by further therapy with 13 cis-retinoic acid treatment.
MIBG 7-10 days before initiating the high-dose chemotherapy cycle consisting of busulphan 16 mg/kg and melphalan 140 mg/m 2 followed by PBSC infusion. We compared the toxicity in these patients to that seen in 15 control subjects with neuroblastoma who underwent a PBSC transplant without MIBG therapy. We observed greater toxic involvement of the gastrointestinal system in children treated with I 131 strategy includes inductive chemotherapy, mainly based on ozaphorines and platine derivatives followed by surgery and a consolidation phase including megatherapy with stem cell rescue. Conditioning regimens combining high-dose chemotherapy with total body irradiation have been abandoned due to unsatisfactory results and severe late effects. In a Children's Cancer Group (CCG) study, the event-free survival (EFS) of children receiving high-dose (HD) chemotherapy with peripheral blood stem cell transplantation (PBSC) rescue was 34% reaching 46% when followed by further therapy with 13 cis-retinoic acid treatment. 1 Targeted radiotherapy with I 131 metaiodobenzylguanidine (MIBG) has proven to be active in advanced neuroblastoma (NB) and insertion in the megatherapy regimen is promising. In fact, I 131 MIBG, that concentrates in the neuroblastoma cells, is potentially capable of selectively delivering a substantial radiation dose to neoplastic cells while sparing normal tissues. We report on the feasibility of this approach in 17 patients with advanced NB. Fifteen children with NB receiving a similar myeloablative conditioning regimen without I 131 MIBG are evaluated and reported as controls. Our experience suggests that including I 131 MIBG in the conditioning regimen followed by PBSC rescue in children taking up MIBG is a feasible therapeutic strategy, although attention should be paid to avoiding lung complications.
Patients and methods

Patients' characteristics and first line therapy
From October 1994 to February 2000 17 patients suffering from either stage 3 (one patient) or 4 (16 patients) neuroblastoma and having positive MIBG residual disease were treated with MIBG megatherapy followed by high-dose chemotherapy with PBSC rescue. Ten were females and seven were males. Median age at diagnosis was 3 years (range [1] [2] [3] [4] [5] [6] [7] [8] [9] . Median time between diagnosis and megatherapy was 7 months (range 4-46). NB origin was adrenal in seven cases, retroperitoneal gangliar in seven cases, abdominal in two, and unknown in one.
Bone Marrow Transplantation
Three patients had resistant disease at the time of transplant while the remaining patients had residual disease. ) followed by peripheral blood stem cell mobilisation and harvest.
The remaining children were treated with Italian protocol NB92 (six patients) and NB95 (one patient). Mobilisation was carried out by administering G-CSF at a dose of 10 g/kg after the fifth and/or sixth course of chemotherapy. Due to the persistent positivity of the I 131 MIBG scan patients received radiometabolic therapy before high-dose chemotherapy with PBSC with I 131 MIBG at a median dose of 7 (range 4.1-11.1) mCi/kg 7-10 days before megatherapy. The dose was administered according to body weight, ie 100-125 mCi for patients weighing less than 15 kg; 150-160 mCi for those weighing more than 20 kg. Doses were determined attempting to give at least 2000 cGy to the tumour and possibly less than 200 cGy to the whole body 2 and the estimated radiation dose ranged between 1.9 and 5.1 Gy (median 2.9). The high-dose chemotherapeutic preparative regimen consisted of busulphan 16 mg/kg and melphalan 140 mg/m 2 in all cases and was followed by PBSC rescue with a median of 4.7 (range 1.7-9) × 10 6 /kg CD34 + cells. Surgery before MIBG therapy on the primary tumor was radical in three children, resulted in partial excision in three patients and was considered unfeasible in 11 patients.
Characteristics of the control subjects
Data concerning 15 patients suffering from either stage 3 (two patients) or 4 (13 patients) neuroblastoma treated between July 1993 and October 1999 were used as controls. These patients did not receive I 131 MIBG therapy since they proved to be negative at MIBG evaluation. Eight of them were males and seven were females. Median age at diagnosis was 3 years (range 0-5). The original tumour was adrenal in eight cases and in the retroperitoneal ganglia in seven. They were treated according to the Italian neuroblastoma protocol NB 92 in seven cases, NB95 in three cases and NB97 in five. Eleven out of 15 patients underwent radical surgery, whereas in the remaining children surgery was partial (two cases) or unfeasible (two cases). Nine patients in CR and five in PR received HD chemotherapy. One patient had resistant disease. They underwent PBSC rescue after a conditioning regimen consisting of busulphan 16 mg/kg and melphalan 140 mg/m 2 in 11 cases, or busulphan at the same dosage, thiotepa 10 mg/kg and melphalan 120 mg/m 2 in four children.
Toxicity
Toxicity was evaluated according to the Bearman score. 3 Engraftment was defined as the first of 3 consecutive days on which neutrophil and platelet counts reached 500/l and 50 000/l, respectively. We considered the toxic involvement of the mucosae and the gastrointestinal system also by comparing the duration of parenteral nutrition. Infections were studied by comparing the duration of fever and antibiotic treatment in the two groups. Pulmonary, hepatic, and CNS toxicity were also studied.
Follow-up
After therapy follow-up was carried out according to the Italian protocol which includes bone marrow evaluation, ecography and NB markers every 3 months. Patients treated with MIBG also received MIBG scans every 6 months.
Results
Recovery
Haematological recovery was similar in both groups. Neutrophil and platelet engraftment were reached at a median time of 12 days (range 9-27 in the MIBG group and 9-20 in the control group) and 17 days (range 13-50 in the MIBG group and 12-36 in the control group), respectively.
Toxicity
Mucosal toxicity occurred in all patients. In 13 out of the 17 patients receiving MIBG it was grade 2 (eight cases) or 3 (five cases). Nine of 15 patients in the control group developed grade 2 (seven cases) or 3 (two cases) mucositis. Gastrointestinal involvement occurred in 12 out of the 17 patients who received megatherapy. It was of grade 1 or 2 in seven and five patients, respectively. Patients in the control group showed a lower incidence of gastrointestinal involvement. In fact, only five out of 15 patients developed grade 1 (two cases) or 2 (three patients) toxicity. Consequently, parenteral nutrition was on average shorter (12 days, range 8-20) as compared to the MIBG group (14 days, range 11-28).
All patients developed infections. Fever lasted an average of 6.5 days (range 1-23) and 5.5 days (range 1-12) in children receiving MIBG and in controls, respectively. Median duration of antibiotic therapy was 11 days (range 8-30) in the first group and 11.5 days (range 7-19) in the second.
Pulmonary complications occurred in two children receiving MIBG. In one case it was transient interstitial pneumonia. The second child developed fatal pneumonia after two further courses of MIBG administered after PBSC transplant. Post-therapy scans did not reveal lung uptake in any of the patients. Lung toxicity was absent in the control group. Two children, one per group, developed grade 1 hepatic toxicity.
Haematological recovery and organ toxicity were not related either to the MIBG dose or to the estimated radiation dose to the patient.
Outcome
Six of 17 patients receiving MIBG relapsed at a median of 18 months from PBSC. In two cases bone marrow was the only site of relapse. Bone marrow lesions were associated with bone metastases and primary relapse in two and one patients, respectively. One child had bone relapse. Two of them are now dead and four are alive with either progressive disease (three cases) or residual disease (one case). The remaining children are alive disease-free (six cases) or with residual disease (five cases) as shown in Table 1 . Median follow-up for this group was 12 months (range 6-63).
As for the control group, 7/15 relapsed at a median of 3 months from PBSC. In five cases relapse involved both bone marrow and skeleton. The remaining two children relapsed in the primary lesion and bone marrow, respectively. All of them died of disease progression. The remaining eight patients are alive disease-free after a median follow-up of 24 months (range 4-80).
Discussion
In the last few years metabolic radiotherapy including MIBG has been used in the treatment of advanced neuroblastoma in order to enhance the effects of chemotherapy.
The main issue involving this therapeutic approach is to demonstrate its true value and to offset the increased toxicity. 4 In fact, it has been demonstrated that I 131 MIBG therapy effectiveness and toxicity may depend on the tumour size. Beta particles with a path length of 800 m may irradiate neighbouring cells, especially when the tumour size decreases. In these cases most of the energy is not absorbed by the target cells but by the nearby ones. The high incidence of haematological toxicity may be accounted for by the radiation crossfire to the bone marrow cells from MIBG targeted cells. Months from graft. RPG = retroperitoneal ganglia; PR = partial remission; MR = minor response; BM = bone marrow; B = bone, P = primary; SD = stable disease; PR = partial remission; CR = complete remission; VGPR = very good partial remission; AWD = alive with disease; DWD = dead with disease; AWPD = alive with progressive disease; AWRD = alive with residual disease; ADF = alive disease free. Results for control: Control group patients received HD chemo in CR (9), PR (5) or resistant disease (1) . Seven relapsed at a median of 3 months from BMT.
Bone Marrow Transplantation
Adding cycles of MIBG to the conditioning regimen might enhance the effects of chemotherapy, although there is an actual risk of toxicity. Moreover, recent reports suggest that cisplatin can enhance radiosensitivity to I 131 -MIBG by inhibiting the DNA repair of potentially lethal radiation-damaged tumor tissues. Furthermore, cisplatin administration at least 1 week after MIBG therapy would avoid the overlapping of toxic consequences of both therapies on the bone marrow. 5 Dose escalation studies 6 have shown that a dose of 15 mCi/kg leads to haematological toxicity requiring PBSC rescue. However, the non-haematological toxicity should also be taken into consideration.
Upon studying a multi-modality approach in five children, Gaze et al 7 demonstrated that the use of MIBG radiotherapy combined with high-dose chemotherapy and total body irradiation was feasible and well tolerated. In a pilot study, side-effects of MIBG treatment associated with highdose chemotherapy and immunotherapy also proved to be tolerable in 11 children. 8 We evaluated the toxicity observed in patients receiving a course of MIBG radiotherapy and a conditioning regimen including high-dose chemotherapy before autologous PBSC transplantation and compared it to that observed in children not receiving MIBG.
Results show that patients receiving MIBG in the conditioning regimen develop higher, although tolerable gastrointestinal and mucosal toxicity. Nevertheless, two children who received MIBG developed transient interstitial pneumonia which was fatal for one of them. However, in the latter case, three courses of MIBG had been administered after two cycles of high-dose chemotherapy. In this case, the grade of toxicity should not be compared to the other patients since it involves an overtreated patient. We cannot claim that there is an increased risk of pulmonary complications on account of the small number of patients. In fact, it is well known that a slight risk of interstitial pneumonia exists in patients who undergo high-dose chemotherapy regardless of any metabolic radiotherapy. 9, 10 However the presence of radioactive compounds in the lungs may worsen a pre-existing immunodeficiency leading to a growth of opportunistic agents. 11 The increased risk of pneumopathy reported in lymphoma patients treated with 131 I-charged monoclonal antibodies could support this hypothesis. 12 Moreover, radioactive compounds are observed in the lungs very early on. We did not observe lung uptake in any patient but we performed MIBG scans approximately 10 days after therapy.
Our experience shows that the risk of usually rare consequences however, does exist.
As for haematological toxicity, the period of neutrophil and platelet recovery was similar in both groups. This is in contrast with data presented in other studies 13 which showed either slower or no recovery of platelets and red blood cells associated with particular risk factors. This difference could be connected to the patients' disease status and to previous treatments which seemed to be more favourable in our study group. The rate of local relapse was similar and low in both groups. However, although most of the control patients were in complete remission, in two cases relapse involved primary lesions, whereas in patients treated with MIBG, all but one having primary lesions, only one relapsed both locally and in bone marrow.
Megatherapy including MIBG radiotherapy provided good control of primary lesions but not of micrometastases, probably due to the varying effectiveness related to the target size.
Radiotherapy including total body irradiation proved to be unsatisfactory 14 and, moreover, predisposed to a high risk of late effects. 15 Longer follow-up is needed to evaluate the incidence of late effects such as hypothyroidism and secondary tumors after metabolic radiotherapy.
All these data suggest that MIBG associated with the conditioning regimen before autologous PBSC is a feasible option to improve the survival of these children. The risk of higher toxicity would appear to be reasonably acceptable. Prospective studies are needed to show the real efficacy of this kind of therapy.
